Why Axsome Therapeutics Depression Study Is All Smiles
Axsome shares absolutely exploded on Monday after the company announced that its midstage trial in patients with major depressive disorder met its primary endpoint.
All Work
Chris Lange
Poseida Therapeutics Gears Up for IPO
Clinical-stage biopharmaceutical company Poseida Therapeutics has filed with the SEC regarding its initial public offering.
Major Biopharma Catalysts Coming in the First Quarter of 2019
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the first quarter of 2019.
Friday’s Biggest Winners and Losers in the S&P 500
Friday was an incredibly positive day for the broad U.S. markets. All of the major exchanges bounced back after each posting a loss over 2% on Thursday. Crude oil made another big gain in…
Why Merrill Lynch Gave Intel a Huge Upgrade
Intel shares jumped to close out the week in part due to markets in general pushing higher, but also a key upgrade from Merrill Lynch helped as well.
Ultragenyx Wins Big in Blood Sugar Study
Ultragenyx Pharma shares made a handy gain to close out the week after the company announced positive results from its midstage trial for the treatment of glycogen storage disease type Ia.
Will the Selecta Biosciences Restructuring Pay Off?
Selecta Biosciences shares pushed higher on Friday after the company provided an update on its new streamlined structure under its new president and CEO.
Epizyme Wins FDA Approval and Maybe More for Lymphoma Study
Epizyme shares jumped on Friday after the company announced a set of pipeline updates as well as a key update from the FDA.
How Novavax Is Cashing In for Flu Season
Novavax shares jumped early on Friday after the company reported that its midstage flu vaccine had some positive results.
Thursday’s Biggest Winners and Losers in the S&P 500
Thursday was a down day for the broad U.S. markets. After a fairly decent Wednesday, markets as a whole took a sharp turn downward. Perhaps a driving force from this was Apple lowering its…
Teva and Amgen Settle Over Kidney Disease Patent Infringement
Teva Pharmaceutical shares made a handy gain on Thursday after it was announced that the firm has settled with Amgen for its treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on…
Catabasis Gears Up for Late-Stage Duchenne Muscular Dystrophy Trial
Catabasis shares jumped on Thursday after the company provided an update from its late-stage trial for edasalonexent in Duchenne muscular dystrophy.
Big Changes Coming at Atara Biotherapeutics
Atara Biotherapeutics shares dipped on Thursday after the company provided a few business updates.
Are Sesen Bio’s Bladder Cancer Preliminary Results Good Enough?
Sesen Bio shares took a beating on Thursday despite posting positive data for its late-stage trial for patients with high-grade non-muscle invasive bladder cancer.
Why DBV Technologies Is Changing Up Senior Leadership
DBV Technologies shares made a handy gain on Thursday after the company announced that it would be making some changes in its senior leadership ahead of its anticipated resubmission of its Viaskin Peanut Biologics…
Merck’s Blockbuster Cancer Drug Keytruda Wins Multiple Approvals in Japan
Merck shares were relatively unchanged early on Thursday after the firm announced that its blockbuster drug Keytruda reported a series of approvals in Japan.
Wednesday’s Biggest Winners and Losers in the S&P 500
Wednesday was a flat day for the broad U.S. markets. Each of the major exchanges started out the day on a negative note, but as the session went on markets moved higher. Crude oil…
How Chipotle Is Capitalizing on New Year’s Resolutions
Chipotle is looking to capitalize on many people making healthier New Year’s resolutions. The burrito chain is releasing a new collection of Lifestyle Bowls, which cater to different diets that customers may be taking…
Roku Goes All In for New Premium Subscription Service
Roku shares made a handy gain on Wednesday after the company announced that it would be expanding its platform to include Premium Subscriptions.
Stealth Bio Gears Up for IPO
Clinical-stage biotechnology company Stealth Biotherapeutics has filed with the SEC regarding its initial public offering.